Neumora Therapeutics (NASDAQ:NMRA) Issues Earnings Results, Beats Estimates By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA) announced its quarterly earnings data on Friday. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01, FiscalAI reports.

Neumora Therapeutics Trading Down 7.5%

Shares of Neumora Therapeutics stock opened at $1.60 on Friday. The firm has a market capitalization of $296.45 million, a price-to-earnings ratio of -1.20 and a beta of 2.75. Neumora Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $3.65. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09. The stock has a 50 day moving average of $1.61 and a 200 day moving average of $2.12.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NMRA. HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Royal Bank Of Canada lowered their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Wall Street Zen raised shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Friday, July 17th. Finally, Needham & Company LLC reduced their target price on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.57.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Siren L.L.C. lifted its stake in shares of Neumora Therapeutics by 44.3% in the 4th quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after purchasing an additional 1,930,500 shares during the last quarter. Millennium Management LLC increased its position in shares of Neumora Therapeutics by 80.1% during the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Neumora Therapeutics by 24.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock worth $2,588,000 after purchasing an additional 281,926 shares during the last quarter. Ikarian Capital LLC raised its holdings in Neumora Therapeutics by 10,128.9% in the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after buying an additional 1,265,910 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Neumora Therapeutics by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock valued at $1,797,000 after buying an additional 34,818 shares during the period. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.